What is JUNS's market cap?

$3.24M, based on the Nov 4 close of $2.46.

Does Jupiter Neurosciences pay a dividend?

No regular cash dividend has been paid in the last year.

How much of JUNS is sold short?

38.6K shares, 6.0% of float, as of Oct 15, 2026.

What sector is JUNS in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · JUNSHealthcarePharmaceuticals

Jupiter Neurosciences, Inc. Common Stock (JUNS)

$2.46+1.23%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$2.46▼ 97.38% in range

Nov 4, 2025Low $2.05 · High $422.44Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Jupiter Neurosciences closed at $2.46 on Nov 4, up 1.23%, 99.4% below its 52-week closing high. Volume of 19.8K shares was 0.82× its 20-day average (close to normal).

Split-adjusted performance: -14.0% over one month, -91.0% over six months, -97.5% over one year.

In the quarter ended Jun 30, 2026, revenue was $24.25K, with a net margin of -9380.9%.

Short interest was 38.6K shares at the Oct 15 settlement, up 8.9% from the prior report (6.0% of float, 1.0 days to cover).

Market cap$3.2M1.3M shares

Revenue · quarter$24.2K—

Diluted EPS$-4.08—

P/E · TTM—P/S 50.1×

Net margin-9,380.9%Gross 86.9%

Dividend yieldNone

52-week range2.05 – 422.44−99.4% from high

Volume19.8K0.82× 20-day avg

Volatility · 60d128.2%Annualised

Short % of float6.0%1.0 days to cover

Net cash-$6.6KCash $1.5M

Next earnings—Not scheduled

Split-adjusted performance

1W −1.6%1M −14.0%3M −99.4%6M −91.0%YTD −96.8%1Y −97.5%3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum2

Revenue growth—

Net margin6

Value (low P/E)—

Size6

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short38.6K+8.9% vs prior

Days to cover1.0Settled Oct 15

% of float6.0%

Short vol. 10d30.7%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
JUNSJupiter Neurosciences	$2.46	+1.23%	−91.0%	—	−9380.9%	—	$3.2M
MBIOMustang Bio	$0.4138	+1.07%	−44.6%	—	—	—	$3.1M	Compare
SXTP60 Degrees Pharmaceuticals	$0.9563	−5.32%	−42.4%	−32.5%	−1152.6%	—	$3.4M	Compare
GRIGRI Bio	$1.43	−7.14%	−39.4%	—	—	—	$3.1M	Compare
KALAKALA BIO	$0.1781	+2.95%	−96.9%	—	—	—	$3.4M	Compare
MDCXMedicus Pharma	$1.88	−7.39%	−88.7%	—	—	—	$3.6M	Compare
SILOSilo Pharma	$1.33	+3.91%	−78.9%	−100.0%	—	—	$2.9M	Compare
CVKDCadrenal Therapeutics	$1.06	−6.19%	−82.8%	—	—	—	$3.8M	Compare
ONCOOnconetix	$0.6583	+15.69%	−85.4%	−83.9%	−16748.3%	—	$3.9M	Compare

News about Jupiter Neurosciences

All news →

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct OfferingGlobeNewswire Inc. · May 20, 2026Neutral

Quick answers

What does Jupiter Neurosciences do?: Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications.
What is JUNS's market cap?: $3.24M, based on the Nov 4 close of $2.46.
Does Jupiter Neurosciences pay a dividend?: No regular cash dividend has been paid in the last year.
How much of JUNS is sold short?: 38.6K shares, 6.0% of float, as of Oct 15, 2026.
What sector is JUNS in?: Healthcare, in the Pharmaceuticals industry.

About Jupiter Neurosciences

Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.

HQ: Jupiter, FL5 employeesListed Dec 3, 2024jupiterneurosciences.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology